Table 1.
Suggested reference limits for Crohn’s disease.
|
Included populations |
Sick populations |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Unit |
Sex | N | % | Lower | 90%CI | Upper | 90%CI | N | Lower | 90%CI | Upper | 90%CI | Health-associated reference interval |
|
ALP U/L |
F | 158 | 92% | 41 | (36–44) | 139 | (129–164) | 172 | 41 | (36–44) | 142 | (136–220) | 35–105 |
|
ALT U/L |
F | 165 | 96% | 9 | (7-9) | 63 | (43–79) | 172 | 9 | (6-9) | 63 | (51–79) | 10–45 |
|
Bilirubin μmol/L |
B | 251 | 81% | 3 | 3,4(3-4) | 27 | (21-28) | 311 | 3 | (3-4) | 28 | (23–38) | 5–25 |
|
CK U/L |
F | 87 | 100% | 23 | (10-31) | 265 | (139–498) | 87 | 23 | (10-31) | 265 | (139–498) | 35–210 |
|
Creatinine μmol/L |
M | 135 | 94% | 51 | (50–60) | 133 | (110–165) | 144 | 51 | (50–60) | 175 | (133–192) | 60–105 |
| F | 142 | 83% | 39 | (38–43) | 101 | (83–103) | 171 | 39 | (38–43) | 115 | (101–140) | 45–90 | |
|
Ferritin μg/L |
M | 138 | 99% | 15 | (7-18) | 448 | (355–1158) | 139 | 15 | (7-18) | 448 | (355–1158) | 30–383 |
| F | 169 | 99% | 13 | (7-15) | 319 | (262–1045) | 171 | 13 | (7-15) | 319 | (262–1045) | 20–167 | |
|
GT U/L |
B | 223 | 72% | 10 | (10-10) | 185 | (117–227) | 309 | 10 | (10-10) | 210 | (140–308) |
F < 40: 10–45; F ≥ 40: 10–75; M < 40: 10–80; M ≥ 40: 15-115 |
| IgG g/L | F | 81 | 96% | 5.3 | (5.1–6.5) | 17.1 | (15.7–19.8) | 84 | 5.1 | (4.1–6.5) | 17.1 | (15.5–19.8) | 19-50: 6.9-15.7; > 50: 6.1-14.9 |
| Leukocytes x 109/L | B | 202 | 64% | 3.8 | (3.5–4.1) | 12.1 | (11.3–14.5) | 317 | 3.8 | (3.5–4.2) | 16.1 | (12.2-20.9) | 4.1–9.8 |
| Platelets x 109/L | B | 81 | 26% | 141 | (116–179) | 468 | (412–544) | 316 | 133 | (116–148) | 499 | (451–544) | 164–370 |
| TSH mIU/L | M | 111 | 100% | 0.48 | (0.01–0.60) | 4.12 | (3.44–4.87) | 111 | 0.48 | (0.01–0.60) | 4.12 | (3.44–4.87) | 0.24–3.78 |
| F | 149 | 96% | 0.04 | (0.02–0.21) | 3.97 | (3.49–7.04) | 156 | 0.04 | (0.02–0.21) | 4.01 | (3.61–9.79) | 0.24–3.78 | |
|
eGFR ml/min/1.73m2 |
M | 80 | 56% | 60 | (49–75) | 137 | (123–138) | 143 | 33 | (29–46) | 131 | (125–138) | > 60 |
Table presents estimated reference limits for patients with Crohn’s disease for identified populations with more than 80 patients. Italic text indicates reference limits for which 90% confidence intervals of corresponding limits for included populations do not overlap. Age distributions for individual populations are available in Supplemental Table 3.
Sick population: all patients identified as having RA, CD or UC, respectively. Included population: patients identified as having RA, CD or UC but no significant comorbidity. N: number of observations. %: fraction of sick population in the included population. Lower: the 2.5th percentile in the results distribution. Upper: the 97.5th percentile in the results distribution. 90%CI: 90% confidence interval. ALP: alkaline phosphatase. ALT: alanine aminotransferase. CK: creatine kinase. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. GT: gamma-glutamyltransferase. IgG: immunoglobulin G. TSH: thyroid stimulating hormone. eGFR: estimated glomerular filtration rate.